Recombinant Human Antibody (mAb1) is capable of binding to PCSK9, expressed in HEK 293 cells. Expressed as the combination of a heavy chain (HC) containing VH from anti-PCSK9 mAb and CH1-3 region of human IgG1 and a light chain (LC) encoding VL from anti-PCSK9 mAb and CL of human kappa light chain. Exists as a disulfide linked dimer of the HC and LC hetero-dimer under non-reducing condition. This antibody could block interaction of PCSK9 with the epidermal growth factor-like repeat A domain of LDL receptor (LDLR)
Figure 1 In vitro effect of mAb1.
(A) mAb1 induced LDLR protein in HepG2 cells after 24 and 48 h, as assessed by Western blot analysis. (B) mAb1 increased LDLR protein in a HepG2 stable cell line overexpressing PCSK9. Cells were incubated with mAb1 for 24 h. The fold change in a and b was calculated as the ratio of LDLR in the presence of mAb1 to LDLR in the absence of mAb1, after normalization of LDLR to β-actin in each lane. (C) A combination of mAb1 with mevinolin induces LDLR protein more than either treatment alone. HepG2 cells were incubated with mAb1 (1, 3, or 10 μg/mL) with or without mevinolin (0.2 or 1 μg/mL) for 48 h, followed by Western blot analysis of whole-cell lysates. The fold change in c was calculated as the ratio of LDLR in the presence of mAb1 and/or mevinolin to LDLR in the untreated cells, after normalization of LDLR to β-actin in each lane.
Figure 2 Changes in serum total cholesterol after i.v. administration of mAb1 to C57BL/6 mice.
(A) Injection of 10 mg/kg mAb1 caused a statistically significant decrease in TC. Results are expressed as the mean ± SEM, n = 7 per group. (B) mAb1 induced hepatic LDLR protein expression, as assessed by Western blot analysis of pooled liver lysates. The fold change was calculated as the ratio of LDLR in the presence or absence of mAb1 for each time point after normalization of the LDLR to β-actin in each lane. (C) mAb1 dose-dependently lowered serum non-HDL-C in mice expressing huPCSK9 by adeno-associated virus (AAV) (n = 7 per treatment group). Results are expressed as the mean ± SEM. *P < 0.05; **P < 0.01 vs. anti-KLH control antibody at the same time point and dose.
Figure 3 Changes in serum LDL-C after i.v. administration of mAb1 to cynomolgus monkeys.
A single injection of mAb1 led to (A) a significant lowering of serum TC, observed as early as 8 h after administration of mAb1; (B) a significant lowering in serum LDL-C, with maximal lowering observed at 10 days after injection; and (C) a significant lowering of HDL-C at day 3 and day 7. Results are expressed as mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001 vs. anti-KLH control antibody at the same time point, n = 4 per group. (D) Temporal relationship between free circulating PCSK9 levels and serum LDL-C after administration of mAb1.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-H31 | Human Anti-PCSK9 Recombinant Antibody (TAB-H31) | FC, IP, ELISA, Neut, FuncS, IF, IHC | Human IgG2, λ |
TAB-0953CL | Human Anti-PCSK9 Recombinant Antibody (TAB-0953CL) | ELISA | Human IgG1 |
TAB-0954CL | Human Anti-PCSK9 Recombinant Antibody (TAB-0954CL) | WB | Human IgG |
TAB-0959CL | Human Anti-PCSK9 Recombinant Antibody (TAB-0959CL) | ELISA, FC | Human antibody |
TAB-0959CL-F(E) | Human Anti-PCSK9 Recombinant Antibody; Fab Fragment (TAB-0959CL-F(E)) | ELISA, FC | Human Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-H10 | Anti-Human PCSK9 Recombinant Antibody (Bococizumab) | WB, FC, IP, ELISA, Neut, FuncS, IF | IgG2 - kappa |
TAB-H59 | Anti-Human PCSK9 Recombinant Antibody (Ralpancizumab) | Neut, ELISA, IF, IP, FuncS, FC, ICC | IgG2 - kappa |
TAB-764CL | Human Anti-PCSK9 Recombinant Antibody (TAB-764CL) | ELISA | Human IgG |
TAB-0020CL | Anti-Human PCSK9 Recombinant Antibody (LPD1282/LPD1462 {i.e., antibody 1 F11)) | LDL-c uptake assay | Humanized Antibody |
TAB-0957CL-S(P) | Anti-Human PCSK9 Recombinant Antibody scFv Fragment (h7F8) | ELISA | Humanized antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
PABZ-101 | Human Anti-PCSK9 Recombinant Antibody (clone 1D05) | ELISA, WB, Neut | Human IgG2 |
PABL-676 | Human Anti-PCSK9 Recombinant Antibody (PABL-676) | WB, FuncS | Human IgG |
PABL-677 | Mouse Anti-PCSK9 Recombinant Antibody (clone mAb J16) | WB, ELISA, FuncS | Mouse IgG |
PABL-678 | Human Anti-PCSK9 Recombinant Antibody (clone CBL21Q) | ELISA, WB | Human IgG |
PABC-196 | Human Anti-PCSK9 Recombinant Antibody (clone J16) | IF, IP, WB, ELISA | Human IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-0956CL | Anti-Human PCSK9 Recombinant Antibody (m7F8) | ELISA | |
TAB-0956CL-S(P) | Anti-Human PCSK9 Recombinant Antibody scFv Fragment (m7F8) | ELISA | |
TAB-0960CL-S(P) | Anti-Human PCSK9 Recombinant Antibody scFv Fragment (Ab1) | ELISA | Rabbit mAb |
TAB-0956CL-F(E) | Anti-Human PCSK9 Recombinant Antibody Fab Fragment (m7F8) | ELISA | |
TAB-0960CL-F(E) | Anti-Human PCSK9 Recombinant Antibody Fab Fragment (Ab1) | ELISA | Rabbit mAb |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-0080CL-VHH | Anti-Human PCSK9 VHH Single Domain Antibody (PKE2) | FuncS, Inhib, FC, WB | Single domain antibody |
TAB-0081CL-VHH | Anti-Human PCSK9 VHH Single Domain Antibody (PKF8) | FuncS, Inhib, FC, WB | Single domain antibody |
TAB-0082CL-VHH | Anti-Human PCSK9 VHH Single Domain Antibody (PKG1) | FuncS, Inhib, FC, WB | Single domain antibody |
TAB-0083CL-VHH | Anti-Human PCSK9 VHH Single Domain Antibody (P1.70) | FuncS, Inhib, FC, WB | Single domain antibody |
TAB-0084CL-VHH | Anti-Human PCSK9 VHH Single Domain Antibody (PKE1) | FuncS, Inhib, FC, WB | Single domain antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
NEUT-1826CQ | Recombinant Human Anti-PCSK9 Antibody, Unconjugated | Neut | IgG1 |
CAT | Product Name | Application | Type |
---|---|---|---|
MOR-2618 | Hi-Affi™ Recombinant Rabbit Anti-PCSK9 Monoclonal Antibody (DS2618AB) | WB | IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
HPAB-0051-FY-F(E) | Human Anti-PCSK9 Recombinant Antibody; Fab Fragment (HPAB-0051-FY-F(E)) | Inhib | Human Fab, κ |
HPAB-0141-FY-F(E) | Human Anti-PCSK9 Recombinant Antibody (clone YW508.20.33); Fab Fragment | FuncS, In vivo | Human Fab |
HPAB-0152-FY-F(E) | Mouse Anti-PCSK9 Recombinant Antibody; Fab Fragment (HPAB-0152-FY-F(E)) | ELISA | Mouse Fab |
HPAB-0041-WJ-F(E) | Mouse Anti-PCSK9 Recombinant Antibody (clone Ab-3D5); Fab Fragment | ELISA, WB | Mouse Fab |
HPAB-667-FY-F(E) | Human Anti-PCSK9 Recombinant Antibody; Fab Fragment (HPAB-667-FY-F(E)) | Inhib | Human Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
AFC-TAB-758 | Afuco™ Anti-PCSK9 ADCC Recombinant Antibody (Lodelcizumab), ADCC Enhanced | ELISA, FC, IP, FuncS, IF, Neut | ADCC enhanced antibody |
AFC-TAB-H10 | Afuco™ Anti-PCSK9 ADCC Recombinant Antibody (Bococizumab), ADCC Enhanced | FC, IP, ELISA, Neut, FuncS | ADCC enhanced antibody |
AFC-TAB-H59 | Afuco™ Anti-PCSK9 ADCC Recombinant Antibody (Ralpancizumab), ADCC Enhanced | Neut, ELISA, IF, IP, FuncS, FC | ADCC enhanced antibody |
AFC-TAB-H31 | Afuco™ Anti-PCSK9 Recombinant Antibody (AFC-TAB-H31), ADCC Enhanced | FC, IP, ELISA, Neut, FuncS, IF | Human IgG1, λ |
CAT | Product Name | Application | Type |
---|---|---|---|
HPAB-M0312-YC-S(P) | Human Anti-PCSK9 Recombinant Antibody; scFv Fragment (HPAB-M0312-YC-S(P)) | ELISA, Block | Human scFv |
HPAB-AP405-YC-S(P) | Human Anti-PCSK9 Recombinant Antibody (clone 508.20.04b); scFv Fragment | ELISA, FC, WB, FuncS | Human scFv |
HPAB-0511-FY-S(P) | Human Anti-PCSK9 Recombinant Antibody; scFv Fragment (HPAB-0511-FY-S(P)) | Neut | Human scFv |
HPAB-0512-FY-S(P) | Human Anti-PCSK9 Recombinant Antibody; scFv Fragment (HPAB-0512-FY-S(P)) | Neut | Human scFv |
HPAB-0513-FY-S(P) | Human Anti-PCSK9 Recombinant Antibody; scFv Fragment (HPAB-0513-FY-S(P)) | Neut | Human scFv |
There are currently no Customer reviews or questions for PABL-294. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.